Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$75.79 USD

75.79
70,454

+1.02 (1.36%)

Updated Aug 4, 2025 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of +4.17% and +3.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

by Zacks Equity Research

Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.

Zacks Equity Research

Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings

by Zacks Equity Research

The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 1.64% and 1%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 27.59% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Zacks Equity Research

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates

by Indrajit Bandyopadhyay

MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.

Zacks Equity Research

Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is it Apt to Retain HAE Stock in Your Portfolio for Now?

by Zacks Equity Research

Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.

Zacks Equity Research

HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

by Zacks Equity Research

Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings Meet Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 0% and 1.30%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Omnicell Stock a Solid Pick for Your Portfolio Right Now?

by Zacks Equity Research

OMCL stays on investors' radar due to the strong performance of the Advanced Services portfolio.

Zacks Equity Research

ResMed Q2 Earnings and Revenues Beat, Stock Up in Pre-Market

by Zacks Equity Research

RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

Zacks Equity Research

Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up

by Zacks Equity Research

In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.

Zacks Equity Research

DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise

by Zacks Equity Research

Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business.

Zacks Equity Research

Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?

by Zacks Equity Research

QGEN stays on investors' radar due to its robust expansion of testing menu and benefits from strategic ties.

Zacks Equity Research

CALID Arm Growth to Support Bruker Shares Amid Macro Issues

by Zacks Equity Research

BRKR's NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

Zacks Equity Research

Here's Why Haemonetics (HAE) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Is Thermo Fisher Stock Worth Holding on to in Your Portfolio?

by Zacks Equity Research

TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.

Zacks Equity Research

IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch

by Zacks Equity Research

IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma.

Zacks Equity Research

Strategic Acquisitions to Support STERIS Stock Amid Macro Issues

by Zacks Equity Research

STE expects bioprocessing revenues to grow in the second half of fiscal 2025.

Zacks Equity Research

Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market

by Zacks Equity Research

ABT delivers a strong underlying base business performance for the fourth quarter of 2024.